Some positive studies of the novel drugs (i.e., cabozantinib and atezolizumab) reported with a significant efficacy on patients with progressive HCC indicate that MET signaling may involve in the underlying mechanisms for the therapeutical effects exerted by these drugs. Here, MET is linked to hepatocellular carcinoma.